Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ainos Equity Warrants Exp 29 July 2027 AIMDW

Healthcare Biotechnology
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose... see more

Recent & Breaking News (NDAQ:AIMDW)

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Accesswire 12 days ago

Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

Accesswire November 11, 2024

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

Accesswire November 8, 2024

Ainos Reports Third Quarter 2024 Financial Results

Accesswire November 6, 2024

Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets

Accesswire October 28, 2024

Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Accesswire October 24, 2024

Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Accesswire October 7, 2024

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Accesswire September 25, 2024

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome

Accesswire September 24, 2024

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

Accesswire September 23, 2024

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

Accesswire September 20, 2024

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Accesswire September 17, 2024

Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Accesswire September 3, 2024

Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Accesswire August 27, 2024

Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter

Accesswire August 26, 2024

Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Accesswire August 19, 2024

Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024

Accesswire August 12, 2024

Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing

Accesswire August 9, 2024

Ainos Reports Second Quarter 2024 Financial Results

Accesswire August 5, 2024

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Accesswire June 14, 2024